As earnings season gains momentum, next week’s slate features heavyweights across tech, energy, industrials, and consumer sectors, offering a broad pulse on corporate health and macro conditions.

Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over the past decade.

Strength, Questions and 2025 Outlook ...

M Company (MMM) reports better-than-expected Q2 2025 results, raises full-year guidance, driven by growth in all business ...

Pfizer, in partnership with Bristol Myers Squibb, has launched a direct-to-patient sales strategy for Eliquis®, aiming to ...

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

American Express stock has been stable but unspectacular this year, staying in lockstep with the broader market. With ...

Stock indexes closed higher on Wall Street, enough to nudge the S&P 500 and the Nasdaq composite to more records. The S&P 500 ...

Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth ...

The expectation is for Q2 earnings to increase by +5% from the same period last year on +4% higher revenues. This will be a material deceleration from the growth trend of recent quarters and will ...

Jefferies ’ profit declined 40% from a year earlier and per-share earnings fell short of analysts’ expectations, sending the firm’s shares lower by 2.7% in after-hours trading Wednesday.